Compare EXP & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | SRRK |
|---|---|---|
| Founded | 1963 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.6B |
| IPO Year | 1994 | 2018 |
| Metric | EXP | SRRK |
|---|---|---|
| Price | $204.41 | $46.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $227.11 | $56.17 |
| AVG Volume (30 Days) | 322.2K | ★ 1.3M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ 1.18 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | ★ $495,023,000.00 | N/A |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $1.95 | $534.24 |
| P/E Ratio | $18.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $171.99 | $27.07 |
| 52 Week High | $243.64 | $51.63 |
| Indicator | EXP | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 47.90 |
| Support Level | $202.49 | $45.59 |
| Resistance Level | $240.80 | $47.96 |
| Average True Range (ATR) | 5.93 | 1.67 |
| MACD | 0.56 | -0.35 |
| Stochastic Oscillator | 53.98 | 25.92 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.